Cargando…

Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy

BACKGROUND: New treatment strategies are emerging to target DNA damage response pathways in ovarian cancer. Our group has previously shown that the class I biased HDAC inhibitor romidepsin (FK228) induces DNA damage response and has potent cytotoxic effects in ovarian cancer cells. Here, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Andrew J, Cheng, Yi-Qiang, Khabele, Dineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394212/ https://www.ncbi.nlm.nih.gov/pubmed/22531354 http://dx.doi.org/10.1186/1757-2215-5-12

Ejemplares similares

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Thailandepsin A
por: Wang, Cheng, et al.
Publicado: (2011)

Syntheses of Thailandepsin B Pseudo‐Natural Products: Access to New Highly Potent HDAC Inhibitors via Late‐Stage Modification
por: Brosowsky, Jana, et al.
Publicado: (2020)

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
por: Gupta, Vijayalaxmi, et al.
Publicado: (2018)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells
por: Gatla, Himavanth R., et al.
Publicado: (2017)

Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2021)

Disparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas
por: Petersen, Shariska, et al.
Publicado: (2020)

Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers
por: van Haaften, Caroline, et al.
Publicado: (2011)

Blood type, ABO genetic variants, and ovarian cancer survival
por: Cozzi, Gabriella D., et al.
Publicado: (2017)

HDAC6 and Ovarian Cancer
por: Haakenson, Joshua, et al.
Publicado: (2013)

Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo
por: Jang, Samuel, et al.
Publicado: (2017)

Preferential Effect of Akt2-Dependent Signaling on the Cellular Viability of Ovarian Cancer Cells in Response to EGF
por: Khabele, Dineo, et al.
Publicado: (2014)

Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model
por: Wilson, Andrew J, et al.
Publicado: (2013)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells
por: Cho, May, et al.
Publicado: (2013)

Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer
por: Ma, Yan, et al.
Publicado: (2020)

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors
por: Beeghly-Fadiel, Alicia, et al.
Publicado: (2018)

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records
por: Cozzi, Gabriella D., et al.
Publicado: (2016)

Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis
por: Hufnagel, Demetra H., et al.
Publicado: (2020)

Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer
por: Asem, Marwa, et al.
Publicado: (2020)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors
por: Choi, Hyeongjwa, et al.
Publicado: (2017)

PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors
por: Shi, Kaixuan, et al.
Publicado: (2019)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
por: Bandolik, Jan J., et al.
Publicado: (2019)

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer
por: Uddin, Md. Jashim, et al.
Publicado: (2019)

An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients
por: Chang, Ping-Ying, et al.
Publicado: (2017)

Harnessing preclinical models for the interrogation of ovarian cancer
por: Qin, Tianyu, et al.
Publicado: (2022)

Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer
por: Glass, Evan B., et al.
Publicado: (2022)

Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer
por: Hoover, Alyssa A., et al.
Publicado: (2020)

Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells
por: Xiao, Xue, et al.
Publicado: (2018)

Adrenal Gland Metastasis Is an Unusual Manifestation of Endometrial Cancer
por: Zaidi, Syeda Sadia, et al.
Publicado: (2013)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
por: Martinez, Alejandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4sos3u3rk2br03d39u60tn6sk